Can Psychiatrists Prescribe Controlled Substances by Telehealth?

Yes. As of June 2026 you can prescribe Schedule II-V controlled substances by telehealth without ever seeing the patient in person, because the DEA and HHS extended the COVID-era telemedicine flexibilities a fourth time, through December 31, 2026. That covers stimulants for ADHD, benzodiazepines, and the rest of the controlled formulary over a real-time audio-video visit. The flexibility is temporary on paper and has been for five years running, so the practical question is not "is it legal today" but "what do I do the next time it is about to expire." This page answers both, and we update it when the rules move.

This is general information for practice planning, not legal or clinical advice. Controlled-substance prescribing carries real liability, and the rules below interact with your state law and your malpractice policy. Confirm anything load-bearing with your own attorney and carrier before you rely on it.

Can you prescribe controlled substances by telehealth right now?

Yes, through December 31, 2026. A DEA-registered prescriber can issue Schedule II-V controlled medications over a two-way audio-video telemedicine visit without a prior in-person evaluation, as long as the prescription follows DEA rules, your state's rules, and the ordinary standard of care. This is the fourth temporary extension of the pandemic-era flexibilities, and it took effect January 1, 2026.

In plain terms, the workflow most telepsychiatry practices have run since 2020 is still legal. You can take a new ADHD patient entirely by video, confirm the diagnosis, check the prescription drug monitoring program, and send a stimulant to their pharmacy. You do not need to have met them in a physical room first.

Two things are still true underneath the flexibility, and both matter. You need a valid DEA registration, which is one of the non-negotiable line items when you open the doors. And the patient's own state can be stricter than the federal rule, which we cover below. The flexibility removes the federal in-person requirement; it does not remove anything else.

What the Ryan Haight Act actually requires

The Ryan Haight Act is the federal law the flexibilities are suspending. Passed in 2008 after deaths tied to online "no-exam" pharmacies, it says that before you prescribe a controlled substance you must have conducted at least one in-person medical evaluation of the patient, with a short list of narrow exceptions. That is the default the country reverts to if the temporary flexibilities ever lapse without a replacement.

The law was written to stop pill-mill websites, not solo psychiatric practices. That distinction matters for how you read the risk, but it does not change the text. If the flexibilities end and none of the exceptions apply, a video-only first visit is not a lawful basis for a controlled-substance prescription under Ryan Haight.

The one exception worth memorizing is the in-person-exam pathway, because it is the part that survives no matter what the DEA does next. We come back to it in a moment.

Why this keeps almost-expiring, and why it keeps getting extended

The flexibilities live on temporary extensions because the permanent rule is not finished. In January 2025 the DEA proposed a framework of "special registrations" that would let qualifying telehealth prescribers register specifically for remote controlled-substance prescribing, with extra requirements around PDMP checks, identity verification, and data reporting. That proposal drew heavy public comment, was not finalized, and the current administration has not moved it forward. Until a final rule exists, the only way to avoid disrupting care for millions of patients is to keep extending the old flexibility, which is exactly what has happened four times.

Psychiatrists who have watched this cycle since 2020 describe the same pattern every year: anxiety builds as a deadline approaches, then the DEA extends again at the last minute. One physician who oversees a large multi-provider telehealth group relayed that a DEA official, speaking publicly, called another short extension the most realistic outcome, because reverting tens of millions of patients to the pre-2020 rules overnight is not operationally feasible.

Here is the honest read, offered as an observed pattern rather than a prediction: every deadline so far has been extended, and a full reversion to the old framework would be hugely disruptive across psychiatry, pain, and addiction medicine. That is not a guarantee. It is a reason not to dismantle a working practice over a hypothetical before you are told the rule has actually changed.

The one workaround that survives a lapse: the in-person-exam exception

If the flexibilities ever lapse, the durable pathway is simple: a patient who has had at least one qualifying in-person medical evaluation can be prescribed controlled substances by telehealth afterward. The in-person exam can be one you performed yourself, or, under the statute's referral exception, one performed by another DEA-registered practitioner who then refers the patient to you. Once that in-person evaluation exists, the telehealth relationship can continue.

For a telepsychiatry practice, that creates two concrete fallback plans:

• See the patient once. Keep access to a physical space, even a sublet or a borrowed exam room a few days a month, so you can do the one in-person visit that unlocks ongoing telehealth prescribing. Practitioners who already have an office near their patients have the most flexibility here, because the in-person option is always available to them.
• Coordinate with a practitioner who has. For an established ADHD patient, one option is to have the patient's primary care physician write the controlled-substance prescription based on your recommendation while you continue the diagnostic and management relationship. This is a real workaround, but it depends on a willing PCP and clean documentation, so set it up before you need it.

The exact contours of the in-person and referral exceptions are technical, and they are the kind of detail a health-law attorney should confirm for your situation. The point for planning is that the in-person evaluation is the hinge. Everything durable runs through it.

What to do if the flexibilities actually expire

Do not wait for the deadline to think about this. The cleanest contingency plan, the kind malpractice carriers circulate when a deadline approaches, is a short decision tree you can run per patient:

1. Identify who is exposed. Run a list of patients you prescribe controlled substances to who have never had an in-person evaluation with you. Patients who have been seen in person, or who came to you by referral after an in-person exam elsewhere, are already covered. Pure telehealth-only controlled-substance patients are the ones at risk.
2. Offer an in-person visit. For exposed patients within reach of a physical location, schedule the one in-person evaluation that brings them back under the rules. This is the first choice whenever it is feasible.
3. If in-person is not possible, start termination with adequate notice. Patient abandonment is its own liability, so a proper notice period is not optional. Carriers have advised starting the termination process several weeks ahead of a hard deadline, on the order of six weeks, so there is time to give notice, bridge or transfer care, and provide referrals before prescribing has to stop.
4. A "wait and see" posture is defensible, with a tripwire. Given the five-year extension pattern, some prescribers reasonably hold off on disrupting patients until the rule is confirmed. If you take that approach, set a calendar tripwire well before the deadline so you still have time to execute steps 2 and 3 if no extension comes.

On patient communication, the consensus from practices that have lived through several of these cycles is to avoid mass-alarming people prematurely. Answer questions as they arise, keep your own plan ready, and send a general notice only once a change is actually finalized. Frightening a stable panel over a deadline that gets extended every year does more harm than good.

Why your pharmacy refuses a legal telehealth script, and what to say

Pharmacies sometimes refuse to fill a controlled-substance prescription from a telehealth-only prescriber even when the prescription is fully legal. Large chains have turned away telepsychiatry stimulant and benzodiazepine scripts citing an in-person requirement that the federal flexibility had already waived. The refusal is often the pharmacy being overly cautious or applying an internal corporate policy, not the federal rule actually prohibiting the fill.

When it happens, two moves usually resolve it:

• Ask the pharmacist to show you the specific policy they are citing. Often it is an internal chain policy rather than a legal prohibition, and naming that distinction changes the conversation. The current DEA telemedicine guidance documents are public; keeping the relevant one on hand to reference is worth the few minutes it takes.
• Build pharmacy relationships before you need them. A practice with a few hundred patients can manage pharmacy friction through relationships in a way a faceless high-volume operation cannot. Knowing which local and mail-order pharmacies reliably fill your telehealth scripts, and routing patients accordingly, prevents most of these standoffs.

Some pharmacies also balk at out-of-state or out-of-area prescribers independent of any federal rule. That is a separate friction from the Ryan Haight question, and it points back to where your DEA registration and the patient sit, which is a multi-state topic of its own.

State law can be stricter than federal

The federal flexibility does not preempt your state. If a state requires an in-person visit before controlled-substance prescribing, that requirement controls even while the federal waiver is in effect. States set their own telehealth and controlled-substance rules, and they do not reliably mirror the federal framework. At least one state terminated its own controlled-substance telehealth waiver while the federal flexibility was still running, which stranded prescribers who had assumed the federal rule was the whole story.

So check both layers, every time you add a state. Your state medical or osteopathic board is the primary source, and most state medical associations track this actively. The Center for Connected Health Policy maintains a survey of telehealth prescribing rules across all states and is a good starting map. Document the patient's physical location at each telehealth visit, because the patient's location is what determines which state's rules apply.

If you prescribe into multiple states, there is a further question of whether you need a DEA registration in each one, which is a deeper topic than this page. The short version: a single DEA registration was treated as sufficient across states during the flexibilities, and the per-state picture is exactly the kind of thing to confirm for your states before you expand.

Where the software fits, and where it does not

Once a controlled-substance prescription is clinically appropriate and legal, sending it should be one step. Eureka's built-in e-prescribing includes EPCS for Schedule II-V controlled substances, so the act of transmitting the script lives inside the same system as the chart and the visit, instead of a bolted-on second tool. Getting EPCS stood up is one of the things to sequence early when you start a practice, because the identity-proofing step takes real lead time. Note too that your DEA registration and prescribing run under your individual Type 1 NPI, not your practice's Type 2. The software removes the workflow friction. It does not remove the compliance judgment.

Knowing whether a given prescription is allowed, for this patient, in this state, on today's rules, is still your call. No EHR currently watches the DEA's extension clock for you or tracks which of your patients have had a qualifying in-person exam. Treat the tooling as the part that sends a script cleanly, and treat the rules above as the part you own.

The bottom line for 2026

Through December 31, 2026, prescribe controlled substances by telehealth the way you have been, within your state's rules and the standard of care. Keep an in-person option available, because the in-person evaluation is the one thing that survives any change. Have a contingency plan written before the next deadline, not during it. And do not restructure a working practice around a reversion that has not happened in five years of deadlines. When the rule changes for real, this page changes with it.